Quick Answer
Spyre Therapeutics, Inc. reported Research And Development Expense of $58.58 million for the year ending 2022.
- Spyre Therapeutics, Inc. showed an increase of +2.6% in Research And Development Expense from 2021 to 2022.
- This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2023.
- XBRL data for this metric is available from 2014 to 2022 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $1.62 million | Q2 2015: $2.74 million | Q3 2015: $3.13 million | Q1 2016: $3.60 million | Q2 2016: $4.42 million | Q3 2016: $5.39 million | Q1 2017: $4.95 million | Q2 2017: $5.84 million | Q3 2017: $6.24 million | Q1 2018: $6.87 million | Q2 2018: $9.12 million | Q3 2018: $8.93 million | Q1 2019: $14.39 million | Q2 2019: $14.81 million | Q3 2019: $17.84 million | Q1 2020: $14.56 million | Q2 2020: $16.87 million | Q3 2020: $12.45 million | Q1 2021: $11.86 million | Q2 2021: $13.58 million | Q3 2021: $14.85 million | Q1 2022: $16.98 million | Q2 2022: $15.37 million | Q3 2022: $11.98 million | Q1 2023: $13.78 million.
- Over the full 9 years of available data (2014 to 2022), Spyre Therapeutics, Inc.'s Research And Development Expense has grown by 757.7%.
- Historical annual values: Fiscal year 2022: $58.58 million | Fiscal year 2021: $57.07 million | Fiscal year 2020: $59.64 million | Fiscal year 2019: $64.60 million | Fiscal year 2018: $36.72 million | Fiscal year 2017: $22.82 million | Fiscal year 2016: $18.14 million | Fiscal year 2015: $11.45 million | Fiscal year 2014: $6.83 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: